AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 116.7% in January

AstraZeneca PLC (OTCMKTS:AZNCF) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 127,400 shares, a growth of 116.7% from the December 31st total of 58,800 shares. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is presently 15.0 days.

AstraZeneca Stock Down 1.2 %

Shares of AZNCF stock opened at $137.21 on Wednesday. AstraZeneca has a 52 week low of $118.16 and a 52 week high of $175.00. The firm’s 50-day simple moving average is $132.73 and its two-hundred day simple moving average is $147.29.

Institutional Investors Weigh In On AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,001 shares of the company’s stock, valued at approximately $156,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.